Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -2.00%9 PS Ratio is 3.25 as of Aug. 31, 2026, which is 69% below its 10-year median of 10.35. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 934 Biotechnology companies, Qyuns Therapeutics Co ranks better than 76.98% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Qyuns Therapeutics Co's share price is HK$16.66.
Qyuns Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$5.13. Hence, Qyuns Therapeutics Co's PS Ratio for today is 3.25.
The historical rank and industry rank for Qyuns Therapeutics Co's PS Ratio or its related term are showing as below:
HKSE:02509'
s PS Ratio Range Over the Past 10 Years
Min: 3.24 Med: 10.35 Max: 43.83
Current: 3.25
During the past 5 years, Qyuns Therapeutics Co's highest PS Ratio was 43.83. The lowest was 3.24. And the median was 10.35.
HKSE:02509's PS Ratio is ranked better than 76.98% of 934
companies
in the Biotechnology industry
Industry Median: 9.52
vs HKSE:02509: 3.25
Qyuns Therapeutics Co (HKSE:02509) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02509 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Qyuns Therapeutics Co's Share Price of today is HK$16.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Qyuns Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$5.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Qyuns Therapeutics Co (HKSE:02509) has a PS Ratio of 3.25 as of Aug. 31, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Qyuns Therapeutics Co and its competitors. This is 69% below median its historical median of 10.35. Over the past decade, Qyuns Therapeutics Co's PS Ratio has ranged from 3.24 to 43.83. According to the industry distribution chart, Qyuns Therapeutics Co ranks #215 out of 934 companies in the Biotechnology industry, placing it in the top 23%.
Is Qyuns Therapeutics Co's PS Ratio too high?
Qyuns Therapeutics Co's current PS Ratio of 3.25 is 69% below median its 10-year median of 10.35. Over the past 10 years, this metric has ranged from a low of 3.24 to a high of 43.83. The Biotechnology industry median PS Ratio is 9.52. Qyuns Therapeutics Co's value of 3.25 is 65.9% below this industry median. Based on the distribution chart, Qyuns Therapeutics Co ranks #215 out of 934 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #215 out of 934 companies for PS Ratio. This places Qyuns Therapeutics Co in the top 23% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.52. Qyuns Therapeutics Co's value of 3.25 is 65.9% below this benchmark. Historically, Qyuns Therapeutics Co's own PS Ratio has ranged from 3.24 to 43.83 over the past decade. While the company's 10-year median is 10.35 vs. the industry median of 9.52, Qyuns Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qyuns Therapeutics Co's current PS Ratio of 3.25 is 65.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current PS Ratio is 3.25, which is 69% below median its own 10-year median of 10.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current PS Ratio of 3.25. The current PS Ratio is 3.25, which is 69% below median its 10-year median of 10.35 and 65.9% below the Biotechnology industry median of 9.52. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current PS Ratio is 3.25 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
